The Current Ratio as of November 2024 (TTM) for REGENXBIO Inc. (RGNX) is 3.05

According to REGENXBIO Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.05. This represents a change of -4.20% compared to the average of 3.18 of the last 4 quarters.

REGENXBIO Inc. (RGNX) Historical Current Ratio (quarterly & annually)

How has RGNX Current Ratio performed in the past?

The mean historical Current Ratio of REGENXBIO Inc. over the last ten years is 9.06. The current 3.05 Current Ratio has changed 3.27% with respect to the historical average. Over the past ten years (40 quarters), RGNX's Current Ratio was at its highest in in the September 2015 quarter at 40.60. The Current Ratio was at its lowest in in the December 2014 quarter at 0.33.

REGENXBIO Inc. (RGNX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of REGENXBIO Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

REGENXBIO Inc. (RGNX) Average Current Ratio

How has RGNX Current Ratio performed in the past?

The current Current Ratio of REGENXBIO Inc. (RGNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

REGENXBIO Inc. (RGNX) Current Ratio vs. Peers

How is RGNX’s Current Ratio compared to its peers?

REGENXBIO Inc.’s Current Ratio is less than Day One Biopharmaceuticals, Inc. (14.62), less than Replimune Group, Inc. (10.11), less than Mirum Pharmaceuticals, Inc. (3.34), less than Rocket Pharmaceuticals, Inc. (6.05), less than Avidity Biosciences, Inc. (17.76), less than uniQure N.V. (6.51), less than Protagonist Therapeutics, Inc. (10.70), less than Pliant Therapeutics, Inc. (10.26), less than Immunocore Holdings plc (3.78), less than Revolution Medicines, Inc. (14.24), less than Monte Rosa Therapeutics, Inc. (6.03), less than Stoke Therapeutics, Inc. (5.09), less than AN2 Therapeutics, Inc. (9.75), less than Passage Bio, Inc. (5.15), less than 4D Molecular Therapeutics, Inc. (17.33), less than Crinetics Pharmaceuticals, Inc. (16.38), less than LianBio (10.06), less than Kezar Life Sciences, Inc. (7.65),

Build a custom stock screener for REGENXBIO Inc. (RGNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like REGENXBIO Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

REGENXBIO Inc. (RGNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like REGENXBIO Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.